Jasper Therapeutics, Inc. Logo

Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):
US4718712023 (+3 more)
LEI:
Country:
United States of America
Address:
2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Radiopharm Theranostics Ltd Logo
Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.
United States of America
RADX
Rallybio Corp Logo
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
United States of America
RLYB
Rani Therapeutics Holdings, Inc. Logo
Develops a capsule to convert injectable biologics into oral pills for chronic diseases.
United States of America
RANI
Rapport Therapeutics, Inc. Logo
Developing precision small molecule medicines for Central Nervous System (CNS) disorders.
United States of America
RAPP
RAPT Therapeutics, Inc. Logo
Developing immune-targeting therapies for inflammatory and immunologic diseases.
United States of America
RAPT
Recordati Industria Chimica e Farmaceutica Logo
Global pharma group developing drugs for common/rare diseases & supplying APIs worldwide.
Italy
REC
RECURSION PHARMACEUTICALS, INC. Logo
AI-driven biotech accelerating drug discovery for rare diseases and oncology.
United States of America
RXRX
RedHill Biopharma Ltd. Logo
Develops oral drugs for GI, infectious diseases, and pandemic preparedness.
United States of America
RDHL
Regencell Bioscience Holdings Ltd Logo
Develops TCM-based therapies for neurocognitive disorders like ADHD and ASD.
United States of America
RGC
REGENERON PHARMACEUTICALS, INC. Logo
A biotech firm inventing, developing, and commercializing medicines for serious diseases.
United States of America
REGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.